Journal of the Korean Society of Food Science and Nutrition (한국식품영양과학회지)

The Korean Society of Food Science and Nutrition (한국식품영양과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Ethanol Extracts of Cinnamon on the Proliferation and COX-2 Pathway in HT-29 Human Colon Cancer Cell Line

육계 에탄올 추출물이 HT-29 대장암 세포주의 성장 및 COX-2 기전에 미치는 영향

  • 이승연 ((주) KMSI 부설 한국의과학연구소) ;
  • 김희석 ((주) KMSI 부설 한국의과학연구소) ;
  • 김정옥 ((주) KMSI 부설 한국의과학연구소) ;
  • 황성완 ((주) KMSI 부설 한국의과학연구소) ;
  • 황성연 ((주) KMSI 부설 한국의과학연구소)
  • Published : 2006.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The effect of cinnamon ethanol extract (CN) on HT-29 cancer cell line has been examined. CN inhibited the growth of HT-29 colon cancer cells in a concentration and time dependent manner but not the growth of CCD-112CoN normal colon cells. And CN markedly inhibited the production of $PGE_2$ and cGMP as well as the mRNA expression of COX-2. These data suggest that non toxic concentration of CN has a significant inhibition effect on the growth of HT-29 cells, probably through the inhibition of $PGE_2$ production via COX-2 inhibition, and may have value as a safe chemopreventive agent for colon cancer.

육계 추출물의 대장암 세포에 미치는 영향을 HT-29 인체 결장암 세포주를 이용하여 조사하였다. 육계 추출물은 대장 정상세포인 CCD-112CoN의 성장에는 크게 영향을 미치지 않았으나, 대장암 세포인 HT-29의 성장은 농도, 시간에 의존적으로 크게 억제하였고, 대장암의 진행 과정에서 매우 중요한 COX-2 mRNA 발현량 및 $PGE_2$ 생성, cGMP 생성을 농도 의존적으로 억제하였다. 이상의 결과에서 육계 추출물은 정상세포에는 독성 없이 대장암 세포의 COX-2 및 $PGE_2$, cGMP 생성을 억제함으로써 결과적으로 대장암 세포의 성장을 감소시킨 것으로 판단된다. 따라서 육계는 부작용이 없는 대장암 예방 건강 보조식품으로서 개발 가능성이 있으며, 암세포 사멸에 대한 더욱 정확한 작용기전의 규명과 활성성분의 분리 및 정제, 응용법 등의 연구가 필요할 것으로 사료된다.

Keywords

References

  1. 대한민국 보건복지부. 2003. 한국인 암등록 조사자료 분석 보고서
  2. Steinbach G, Lynch PM, Phillips RKS, Kelloff G. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952 https://doi.org/10.1056/NEJM200006293422603
  3. Kaza CS, Kashfi K, Rigas B. 2002. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins Other Lipid Mediat 67: 107-120 https://doi.org/10.1016/S0090-6980(02)00003-5
  4. Thun MJ, Hrnley SJ, Patrono C. 2002. Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266 https://doi.org/10.1093/jnci/94.4.252
  5. Meyskens FLJ, Gerner EW. 1995. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5: 945-951
  6. Kathryn RL, Natalia AI, Gary AP, Hiayan C, Eugene WG. 2000. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epiderm Biomarkers Prev 9: 1155-1162
  7. Grodstein F, Martinez ME, Platz EA. 1998. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128: 705-712 https://doi.org/10.7326/0003-4819-128-9-199805010-00001
  8. Borgelt L, Umland E. 2004. Benefits and challenges of hormone replacement therapy. J Am Pharm Asso Wash 40: 30S-31S
  9. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. 1998. The chemoptrventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 134: 129-139 https://doi.org/10.1016/S0304-3835(98)00248-1
  10. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. 1999. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Cancer Res 18: 259-266
  11. Gibson TB, Ranganathan A, Grothey A. 2006. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6: 29-31 https://doi.org/10.3816/CCC.2006.n.01
  12. Pettinari A, Amici M, Cuccioloni M, Angeletti M, Fioretti E, Eleuteri AM. 2006. Effect of polyphenolic compounds on the proteolytic activities of constitutive and immuno- proteasomes. Antioxid Redox Signal 8(1-2): 121-129 https://doi.org/10.1089/ars.2006.8.1
  13. Carole LW, Kathleen JH, Patricia AL, Brigid LMH, Lynn MM. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402-1407
  14. Yamamoto K, Higashi S, Kioi M, Tsunezumi J, Honke K, Miyazaki K. 2006. Binding of active matrilysin to cell surface cholesterol sulfate is essential for its membrane- associated proteolytic action and induction of homotypic cell adhesion. J Biol Chem 281: 9170-9180 https://doi.org/10.1074/jbc.M510377200
  15. Narisawa T, Morotomi M, Fukahara Y, Hasebe M, Ito M, Aizawa R. 1996. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87: 798-804 https://doi.org/10.1111/j.1349-7006.1996.tb02103.x
  16. Notarnicola M, Messa C, Pricci M, Guerra V, Altomare DF, Montemurro S, Caruso MG. 2004. Up-regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res 24: 3837- 3842
  17. Marnett LJ, DuBois RN. 2002. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42: 55-80 https://doi.org/10.1146/annurev.pharmtox.42.082301.164620
  18. 김영중, 김종원, 김창민, 도상학, 배기환, 성충기, 신승원, 유경수, 유승조, 육창수, 이경순, 이숙연, 이정규, 임종필, 정보섭, 한대석. 1998. 생약학. 동명사, 서울. Vol 11, p 110-113
  19. Mina T, Robert A, Ishak N. 1999. Cinamon extract's inhibitory effect on Helicobacter pylori. J Ethnopharmacology 67: 269-277 https://doi.org/10.1016/S0378-8741(99)00054-9
  20. Schene NW, Kelly MA, Marilyn MP, Anderson RA. 2005. Water-soluble polymeric polyphenols from cinnamon inhibit proliferation and alter cell cycle distribution patterns of hematologic tumor cell lines. Cancer Lett 230: 134-140 https://doi.org/10.1016/j.canlet.2004.12.039
  21. Chung HR, Lee JY, Kim DC, Hwang WI. 1999. Synergistic effect of Panax ginseng and Cinnamon blume mixture on the inhibition of cancer cell in vitro. J Ginseng Res 23: 99-104
  22. Mosmann T. 1983. Rapid colorimetric assay for the cellular growth and survival; application to proliferation and cytotoxic assay. J Immun Methods 65: 56-58
  23. Yasuhide M, Minoru I, Akihiko S, Noriko F, Yoshikazu I, Hitoshi A, Kohji H. 2000. Potential role of group X secretory phospholipase $A_2$ in cyclooxygenase-2-dependent PGE2 formation during colon tumorigenesis. FEBS Lett 487: 262-266 https://doi.org/10.1016/S0014-5793(00)02350-4
  24. Baron JA, Cole BF, Sandler RS. 2003. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899 https://doi.org/10.1056/NEJMoa021735
  25. Benamouzig R, Deyra J, Martin A. 2003. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one year results of the APACC trial. Gastroenterology 125: 328-336 https://doi.org/10.1016/S0016-5085(03)00887-4
  26. Hawk E, Lubet R, Limburg P. 1999. Chemoprevention in hereditary colorectal cancer syndrome. Cancer 86: 2551S- 2563S https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<551::AID-CNCR1>3.0.CO;2-I
  27. Zhao LP, Kushi LH, Klein RD, Prentice RL. 1991. Quantitative review of studies of dietary fat and rat colon carcinogenesis. Nutr Cancer 15: 169-177 https://doi.org/10.1080/01635589109514124
  28. Torzsas TL, Kendall CWC, Sugano M, Iwamoto Y, Rao AZ. 1996. The influence of high and low molecular weight chitosan on colonic cell proliferation and abberent crypt foci development in CFI mice. Fd Chem Toxicol 34: 73-77 https://doi.org/10.1016/0278-6915(95)00083-6
  29. Pereira MA, Barnes LH, Steele VE, Kellof GV, Lubet R. 1996. Piroxicam-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 17: 373-376 https://doi.org/10.1093/carcin/17.2.373
  30. Craven PA, Saito R, Derubertis FR. 1983. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 72: 1365-1375 https://doi.org/10.1172/JCI111093
  31. Cianchi F, Cortesini C, Fantappiè O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Felice AD, Perigli G, Mazzanti R, Masini E. 2004. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10: 2694-2704 https://doi.org/10.1158/1078-0432.CCR-03-0192
  32. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. 1996. Peroxynitrite, the coupling product of nitric oxide and superoxide antivates prostaglandin biosynthesis. Proc Natl Acad Sci USA 93: 15069-15074
  33. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N. 2001. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7: 1325-1332
  34. Bing RJ, Miyataka M, Rich KA, Hanson N, Wang X, Slosser HD, Shi S-R. 2001. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin Cancer Res 7: 3385-3392
  35. Wapnir RA, Teichberg S. 2002. Regulation mechanism of intestinal secretion: implications in nutrient absorption. J Nut Biochem 13: 190-199 https://doi.org/10.1016/S0955-2863(02)00181-X
  36. Schmidt HHHW, Lohmann SM, Walter U. 1993. Nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1178: 153-175 https://doi.org/10.1016/0167-4889(93)90006-B
  37. Lincoln TM, Komalavilas P, Boerth NJ, MacMillanCrow LA, Cornwell TL. 1995. cGMP signaling through cAMP- and cGMP-dependent protein kinase. Adv Pharmacol 34: 305-322 https://doi.org/10.1016/S1054-3589(08)61094-7

Cited by

  1. Quality and Antioxidant Properties of Cookies Supplemented with Cinnamon Powder vol.43, pp.9, 2014, https://doi.org/10.3746/jkfn.2014.43.9.1457
  2. Anti-inflammatory and apoptosis improving effects of sulfasalazine and Cinnamomi cortex and Bupleuri radix mixture in TNBS-induced colitis mouse model vol.60, pp.3, 2017, https://doi.org/10.3839/jabc.2017.036
  3. 닭고기의 품질 및 맛에 관한 계피 급여효과 vol.37, pp.5, 2006, https://doi.org/10.3746/jkfn.2008.37.5.618
  4. 누에와 육계 복합 추출물의 in vivo 면역증진 기능성 연구 vol.33, pp.4, 2006, https://doi.org/10.6116/kjh.2018.33.4.19